Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 147 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: CKD Anemia Clear all
Completed Phase 1 Interventional

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

NCT02805244
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, 14C-JTZ-951
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Jul 23, 2026, 8:59 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

NCT03619850
View directory record Official record
Conditions
Chronic Kidney Disease; Iron Deficiency Anemia
Interventions
Ferumoxytol, Iron sucrose
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
8
States / cities
Hollywood, Florida • Detroit, Michigan • Kansas City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

NCT01977482
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, Placebo, rhEPO
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Azusa, California • Los Angeles, California • San Dimas, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Phase 1 Interventional

Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease

NCT01978587
View directory record Official record
Conditions
Anemia in Chronic Kidney Disease
Interventions
JTZ-951
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Jul 23, 2026, 8:59 PM EDT
Withdrawn Phase 4 Interventional

Safety Assessment of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)

NCT01151592
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Iron Sucrose
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

NCT02689206
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, GSK1278863 matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Northridge, California • San Dimas, California • Pembroke Pines, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Jul 23, 2026, 8:59 PM EDT
Not listed Not applicable Interventional

Assessment of an Anemia Model Predictive Controller for Anemia Management in Hemodialysis Patients

NCT04360902
View directory record Official record
Conditions
End Stage Renal Disease, Renal Anemia, Chronic Kidney Diseases
Interventions
Anemia Controller
Other
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis

NCT02243306
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Lakewood, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Phase 3 Interventional Results available

VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

NCT00317239
View directory record Official record
Conditions
Anemia
Interventions
Ferrous Sulfate tablets, Ferric Carboxymaltose (FCM)
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
12 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Jul 23, 2026, 8:59 PM EDT
Withdrawn Phase 3 Interventional

Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

NCT03242967
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Northridge, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Jul 23, 2026, 8:59 PM EDT
Completed No phase listed Observational

Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease

NCT01719146
View directory record Official record
Conditions
Anemia of End Stage Renal Disease
Interventions
Specimen collection
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
3
States / cities
Louisville, Kentucky • Springfield, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis

NCT00598273
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Darbepoetin alfa
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
68
States / cities
Montgomery, Alabama • Tempe, Arizona • Hot Springs, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Not applicable Interventional Results available

Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency

NCT02888171
View directory record Official record
Conditions
Chronic Kidney Disease, Iron Deficiency, Anemia
Interventions
ferric citrate, ferrous sulfate
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Phase 2 Interventional

A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis

NCT05265325
View directory record Official record
Conditions
Renal Anemia
Interventions
AND017 capsules TIW, AND017 capsules QW, epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars
Drug
Lead sponsor
Kind Pharmaceuticals LLC
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
10
States / cities
Pine Bluff, Arkansas • Riverside, California • Lone Tree, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Jul 23, 2026, 8:59 PM EDT
Terminated Phase 4 Interventional Results available

A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease

NCT00830037
View directory record Official record
Conditions
Chronic Kidney Disease, Iron-deficiency Anemia
Interventions
IV Iron, Ferrous Sulfate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Phase 3 Interventional Results available

PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients

NCT00440466
View directory record Official record
Conditions
Anemia, Renal Diseases
Interventions
epoetin alfa
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
66
States / cities
Chula Vista, California • Fountain Valley, California • Los Angeles, California + 63 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

NCT00597584
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Epoetin alfa or Epoetin beta
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
823 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • McGehee, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease

NCT03992066
View directory record Official record
Conditions
Anemia Associated With Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa, Epoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
Escondido, California • Denver, Colorado • Fort Lauderdale, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Phase 3 Interventional Results available

KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD

NCT02268994
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
ferric citrate, Placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
36
States / cities
Phoenix, Arizona • Tempe, Arizona • Glendale, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Early Phase 1 Interventional

Losartan for Sickle Cell Kidney Disease

NCT01989078
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Losartan
Drug
Lead sponsor
Emory University
Other
Eligibility
9 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2017 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis

NCT00598442
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Darbepoetin alfa
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
42
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Phase 2 Interventional Results available

Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis

NCT01736397
View directory record Official record
Conditions
Iron Deficiency, Iron Deficiency Anemia
Interventions
Ferric Citrate, Placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
20
States / cities
Tempe, Arizona • La Mesa, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Jul 23, 2026, 8:59 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

NCT02892149
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3,554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
127
States / cities
Huntsville, Alabama • Mesa, Arizona • Pine Bluff, Arkansas + 95 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Jul 23, 2026, 8:59 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

NCT00454246
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta, epoetin alfa, darbepoetin alfa
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
78
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Jul 23, 2026, 8:59 PM EDT